Vancomycin-resistant Enterococcus faecalis
% Resistant in 2024
3.6% Resistant
Number of Resistant Isolates of the Total Number of Isolates Tested In 2024
273 Resistant
/ 7,539 Tested
% Resistant by Patient Age in 2024
- Pediatric:
- 0.0% Resistant
- Adult:
- 3.8% Resistant
Pathogen Profile
Vancomycin-resistant Enterococcus faecalis
Vancomycin-resistant Enterococcus faecalis cause a range of illnesses, mostly among patients receiving healthcare, including bloodstream infections, surgical site infections, and urinary tract infections. E. faecalis can be resistant to many antibiotics, including vancomycin. Such resistance makes treatment of these infections more difficult.
- Data Source
- National Healthcare Safety Network (NHSN)
- Current Threat Report
Threat LevelSerious
Estimated Cases54,500
Estimated Deaths5,400
Healthcare Costs (USD)$539 M
Source: COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2024
- Years Included
- 2011 - 2024
Geographic Locations
Percent Vancomycin resistance Among E. faecalis by State Map
Percent Vancomycin resistance Among E. faecalis by State
| Location | value |
|---|---|
| Alabama | 2.7 |
| Alaska | Insufficient Data |
| Arizona | 4.7 |
| Arkansas | 0 |
| California | 4.1 |
| Colorado | 0 |
| Connecticut | 5.8 |
| Delaware | 0 |
| District of Columbia | 5.9 |
| Florida | 3.2 |
| Georgia | 3.9 |
| Hawaii | 0 |
| Idaho | 3 |
| Illinois | 2.7 |
| Indiana | 0 |
| Iowa | 0 |
| Kansas | 0 |
| Kentucky | 5.1 |
| Louisiana | 0 |
| Maine | 22.2 |
| Maryland | 5.8 |
| Massachusetts | 11.2 |
| Michigan | 6.9 |
| Minnesota | 0.5 |
| Mississippi | 1.3 |
| Missouri | 3.8 |
| Montana | 0 |
| Nebraska | 0 |
| Nevada | 3.7 |
| New Hampshire | 0 |
| New Jersey | 6.7 |
| New Mexico | 2.9 |
| New York | 7.6 |
| North Carolina | 4.9 |
| North Dakota | 0 |
| Ohio | 2.9 |
| Oklahoma | 6 |
| Oregon | 3.2 |
| Pennsylvania | 2.6 |
| Puerto Rico | 0 |
| Rhode Island | Insufficient Data |
| South Carolina | 6 |
| South Dakota | 2.2 |
| Tennessee | 3.8 |
| Texas | 1.1 |
| Utah | 3 |
| Vermont | 0 |
| Virginia | 2.4 |
| Washington | 2.1 |
| West Virginia | 4.7 |
| Wisconsin | 0.7 |
| Wyoming | Insufficient Data |
Percent Vancomycin resistance Among E. faecalis by State List
Geography
| state | value |
|---|---|
| United States | 3.6% |
| Alabama | 2.7% |
| Alaska | No Data |
| Arizona | 4.7% |
| Arkansas | 0.0% |
| California | 4.1% |
| Colorado | 0.0% |
| Connecticut | 5.8% |
| Delaware | 0.0% |
| District of Columbia | 5.9% |
Changes Over Time in Vancomycin resistance Among E. faecalis
This graph displays percent antimicrobial resistance from 2011 to 2024 for all event types. Blank areas of the chart represent 0% resistance, indicating that zero resistant pathogens were reported for the selected year, phenotype, and HAI type. “Insufficient data” indicates that less than 20 pathogens were isolated and tested for resistance.
| Year | % Resistant |
|---|---|
| 2011 | 7.8 |
| 2012 | 6.8 |
| 2013 | 7 |
| 2014 | 6.6 |
| 2015 | 7.6 |
| 2016 | 6.1 |
| 2017 | 5.3 |
| 2018 | 4.9 |
| 2019 | 4.2 |
| 2020 | 3.5 |
| 2021 | 3.4 |
| 2022 | 3.8 |
| 2023 | 3.7 |
| 2024 | 3.6 |
Healthcare Facility Type
Vancomycin resistance Among E. faecalis by Hospital Type
Percent resistant Among E. faecalis by Hospital Type
| Hospital Type | % Resistant |
|---|---|
| General Acute Care Hospitals | 3.2 |
| Long Term Acute Care Hospitals | 19.5 |
| Inpatient Rehabilitation Facilities | 0 |
Footnotes
- HAIs include Catheter-associated Urinary Tract Infections (CAUTI), Central Line-associated Bloodstream Infections (CLABSI), and Surgical Site Infections (SSI).
- CI (Confidence Interval) - The national, regional, and state-level data included in Antimicrobial Resistance information are displayed with 95% confidence intervals around the percent resistance, which were calculated using a mid-P exact test and are an indication of precision.
- Map legends are classified using the Jenks Natural Breaks method.